The therapy requirement in the three most advanced psychedelic drug development programs shapes trial design, scalability, and eventual commercial adoption

Therapy requirements sit at the center of the most advanced psychedelic drug development programs and strongly influence cost, clinical operations, regulatory positioning, and future market scale. The comparison focuses on three late-stage programs, where the amount and role of psychotherapy differ and create very different paths to approval and rollout. MDMA-assisted therapy has typically embedded extensive therapist support, making outcomes harder to separate from the drug-plus-therapy package and raising questions about training, reimbursement, and throughput. More scalable models in psilocybin development aim to reduce or standardize therapeutic intensity, which could make treatment easier to deliver but may also change efficacy, safety management, and how regulators interpret benefit. The broader implication is that the field is not only testing molecules. Developers, regulators, and payers are also deciding whether psychedelic treatment will be approved as intensive therapy, as pharmacotherapy with support, or as something in between, with major consequences for access and business viability.